ARGX
No price yet
Announcements
Nothing here yet
Daily updates
- argenx will discontinue its Phase 3 UNITY trial of subcutaneous efgartigimod in moderate-to-severe Sjögren’s disease after an IDMC futility review found it unlikely to meet the Week 48 clinESSDAI primary endpoint; no new safety signals emerged.Oct 9, 2026
- argenx will discontinue the Phase 3 UNITY study of subcutaneous efgartigimod in moderate-to-severe Sjögren's disease after an IDMC futility review found the trial unlikely to meet its Week 48 primary endpoint.Oct 8, 2026
- Vyvgart Hytrulo Phase 3 trial achieved its primary objective in autoimmune myositisAug 17, 2026
FDA designations
Nothing here yet
News
- argenx to present Phase 3 ALKIVIA results in autoimmune myositis as a late-breaking oral presentation at ACR Convergence 2026Oct 19, 2026
- argenx shares decline as a setback in Sjögren's disease offsets progress with its celiac disease drugOct 8, 2026
- argenx provides an update on the Phase 3 UNITY study of subcutaneous efgartigimod in Sjögren's diseaseOct 8, 2026
- argenx reports positive topline Phase 2 results for FB102 in celiac diseaseOct 8, 2026
- argenx presents new AANEM and MGFA data showing earlier and sustained treatment benefits with VYVGART in myasthenia gravis and CIDP, alongside progress across its neuromuscular pipelineSep 29, 2026